The global interventional cardiology and peripheral devices market size is likely to be valued at US$31.2 billion in 2026 and is estimated to reach US$59.2 billion by 2033, growing at a CAGR of 9.6% during the forecast period from 2026 to 2033, driven by the rising prevalence of coronary and peripheral vascular diseases, increasing preference for minimally invasive cardiovascular procedures, and continuous technological developments in stents, catheters, and intravascular imaging systems.

Driver - Increasing Burden of Heart and Vascular Diseases Globally

The rising number of people with Coronary Artery Disease (CAD), Peripheral Arterial Disease (PAD), diabetes, obesity, and hypertension is creating sustained demand for interventional cardiology and peripheral devices. As these conditions progress, several patients require angioplasty, stents, balloons, thrombectomy devices, and atherectomy systems to restore blood flow and avoid major complications.

According to the World Health Organization (WHO), cardiovascular diseases remain the leading cause of death globally, accounting for nearly 20.5 million deaths each year. The American Heart Association (AHA) further reported in 2024 that PAD affects more than 230 million people worldwide, highlighting the urgent need for peripheral vascular interventions. This expanding patient population continues to boost procedure volumes across hospitals and specialty cardiovascular centers.

Rising Shift toward Minimally Invasive Procedures

Patients and physicians today prefer minimally invasive cardiovascular procedures as they offer faster recovery, shorter hospital stays, lower blood loss, and fewer complications than open surgery. These benefits have increased the use of angioplasty, image-guided catheter interventions, drug-eluting stents, and drug-coated balloons for both coronary and peripheral artery disease. Continuous improvements in catheter flexibility, intravascular imaging, and plaque-modification technologies have also improved procedural success in complex cases.

The European Society of Cardiology (ESC) and the American College of Cardiology (ACC) continue to recommend percutaneous coronary intervention for many patients with acute coronary syndromes and selected chronic coronary disease. This supports the wide adoption of interventional devices. Hospitals are also expanding catheterization laboratories to meet rising demand for these procedures.

Restraint - Risk of Repeat Vascular Complications May Limit Wide Treatment Confidence

Although interventional devices have advanced significantly, long-term complications such as vessel re-narrowing and clot formation remain an important challenge. Restenosis can occur as scar tissue develops inside the treated artery. Stent thrombosis may also lead to serious cardiac events if blood clots form around the implanted device. These complications are anticipated to require repeat interventions, thereby increasing healthcare costs and affecting patient confidence.

Physicians often require prolonged antiplatelet therapy to reduce these risks, which may not be suitable for every patient. According to the European Society of Cardiology (ESC) and multiple studies published in the Journal of the American College of Cardiology (JACC), modern drug-eluting stents have greatly reduced these events. However, restenosis and thrombosis continue to be clinical concerns, especially in patients with diabetes or highly calcified lesions.

Opportunity - Advances in Calcium-Modifying Technologies to Expand Treatment Possibilities

The increasing adoption of intravascular lithotripsy (IVL) is creating new opportunities for the market by making it convenient to treat heavily calcified coronary and peripheral arteries. IVL uses controlled sonic pressure waves to fracture calcium in the vessel wall without causing major damage to surrounding tissue. This improves balloon expansion and allows better stent placement in complex lesions that were previously difficult to treat.

Clinical studies such as DISRUPT CAD have demonstrated high procedural success and superior safety outcomes, supporting broad physician adoption. Companies such as Shockwave Medical, now part of Johnson & Johnson MedTech, continue to extend IVL technology into new indications. Such initiatives are predicted to increase its role in complex cardiovascular interventions.

Development of Bioresorbable Implants to Open New Treatment Options

Next-generation bioresorbable scaffolds for below-the-knee (BTK) peripheral artery disease represent a promising opportunity. This is as they provide temporary vessel support before gradually dissolving, leaving no permanent metal implant behind. This approach is predicted to reduce long-term vessel inflammation, preserve future treatment options, and improve natural vessel function.

Interest is particularly high for patients with chronic limb-threatening ischemia, where maintaining long-term blood flow is important. For example, BIOTRONIK's Freesolve Resorbable Metallic Scaffold has shown encouraging early clinical performance in peripheral vascular applications and is expanding the field of bioresorbable vascular therapies. Continued clinical research and technological improvements are anticipated to support the wide adoption of these novel implants in the next ten years.

Product Type Insights

Angioplasty stents are predicted to lead with a share of about 34.7% in 2026, as it provides long-term vessel support after angioplasty and significantly lower the risk of artery re-narrowing. Drug-Eluting Stents (DES) are now the standard of care in most coronary interventions as they slowly release medicines that reduce scar tissue formation inside the artery. Compared with balloon angioplasty alone, modern DES offer better long-term vessel patency and reduce the need for repeat procedures.

Catheters are estimated to be the fastest-growing segment over the forecast period, as every interventional cardiovascular procedure depends on them for safe access, diagnosis, and treatment. Guide catheters, diagnostic catheters, aspiration catheters, and specialty delivery catheters are essential during coronary angioplasty, peripheral interventions, structural heart procedures, and thrombectomy. As hospitals perform more minimally invasive procedures, demand for advanced catheter technologies continues to increase.

Application Insights

The Coronary Artery Disease (CAD) segment is anticipated to dominate with a share of around 48.2% in 2026, as it remains the leading cause of cardiovascular death worldwide and accounts for the largest number of interventional procedures. CAD is caused by plaque buildup in the coronary arteries, reducing blood flow to the heart. Millions of patients require angioplasty and stent implantation every year to restore circulation and prevent heart attacks. The disease is becoming very common due to aging populations and the increasing prevalence of diabetes, hypertension, obesity, and high cholesterol.

The Peripheral Arterial Disease (PAD) segment is expected to remain in the second position in 2026, as more patients are being diagnosed early, and minimally invasive treatment options have improved significantly. PAD affects arteries outside the heart, especially in the legs, and is becoming common due to diabetes, smoking, chronic kidney disease, and aging populations. Rising awareness and better screening are helping physicians identify patients before severe complications develop. Modern endovascular technologies have expanded treatment options for PAD.

North America Interventional Cardiology and Peripheral Devices Market Trends

North America is predicted to dominate globally in 2026 with a share of about 33.5%, as it has a highly developed cardiovascular care network and adopts new medical technologies early. Hospitals across the U.S. and Canada routinely perform complex minimally invasive procedures using advanced stents, intravascular imaging systems, thrombectomy devices, and drug-coated balloons. The region also benefits from a strong presence of leading manufacturers such as Medtronic, Boston Scientific, Abbott, BD, and Teleflex, which launch new products and conduct major clinical studies locally.

U.S. Interventional Cardiology and Peripheral Devices Market Trends

A share of about 67.9% is expected to be held by the U.S. in 2026 in North America as hospitals continue to extend minimally invasive cardiovascular treatments while rapidly adopting innovative devices. Physicians now use drug-eluting stents, Intravascular Ultrasound (IVUS), Optical Coherence Tomography (OCT), and intravascular lithotripsy to improve outcomes in complex coronary and peripheral procedures. The country also benefits from continuous regulatory approvals and superior clinical research activity. The U.S. FDA regularly clears next-generation cardiovascular devices, allowing quick commercialization of innovative technologies.

Asia Pacific Interventional Cardiology and Peripheral Devices Market Trends

Asia Pacific is anticipated to be the fastest-growing region globally in 2026 with a share of around 31.6%, as cardiovascular disease is increasing steadily while healthcare infrastructure is expanding across the region. Governments are investing heavily in specialty cardiac hospitals, catheterization laboratories, and advanced diagnostic facilities. This allows more patients to receive minimally invasive treatment instead of traditional surgery. The region also benefits from improving health insurance coverage, rising healthcare spending, and increasing physician training in interventional cardiology.

China Interventional Cardiology and Peripheral Devices Market Trends

China will likely lead in Asia Pacific in 2026 with a share of around 38.2%, as it is constantly expanding advanced cardiovascular care while strengthening its domestic medical device industry. The country has invested significantly in hospital modernization and the development of high-level cardiovascular centers capable of performing complex coronary and peripheral interventions. China is also encouraging local innovation through supportive regulatory reforms and domestic manufacturing. Companies such as MicroPort Scientific and Lepu Medical continue to broaden their portfolios of coronary stents, balloons, and vascular intervention devices for both domestic and international markets.

India Interventional Cardiology and Peripheral Devices Market Trends

In 2026, India is projected to account for a share of just about 17.4% in Asia Pacific, as access to advanced cardiac care is improving across both metropolitan and small cities. More hospitals are establishing catheterization laboratories and expanding interventional cardiology services, allowing patients to receive fast treatment for coronary artery disease and peripheral vascular disease. Government initiatives are further supporting growth by improving healthcare access and encouraging domestic medical device manufacturing. Programs such as Ayushman Bharat have increased access to cardiac treatment for several patients. The Production Linked Incentive (PLI) Scheme for Medical Devices also supports local manufacturing of advanced healthcare technologies.

Europe Interventional Cardiology and Peripheral Devices Market Trends

Europe will likely witness steady growth over the forecast period, with a share of roughly 17.8% globally in 2026, as it has well-established cardiovascular treatment guidelines and consistently adopts evidence-based technologies. Countries across the region continue to replace old devices with new drug-eluting stents, drug-coated balloons, and advanced imaging systems that improve procedural outcomes. The European Society of Cardiology (ESC) regularly updates clinical guidelines that encourage the use of proven interventional therapies for coronary artery disease and peripheral arterial disease. Europe also has well-established clinical research networks and experienced interventional cardiologists, allowing swift adoption of innovative devices once regulatory approval is obtained.

Germany Interventional Cardiology and Peripheral Devices Market Trends

Germany will likely register a substantial share of roughly 39.2% in 2026 in Europe, backed by its advanced hospital infrastructure and high procedural expertise in interventional cardiology. The country has a large network of specialized cardiovascular centers that routinely perform complex coronary and peripheral interventions using the latest imaging and catheter-based technologies. Germany is also an important location for medical device research and manufacturing. Several multinational companies conduct clinical studies and product launches in the country owing to its experienced physicians and superior healthcare infrastructure.

U.K. Interventional Cardiology and Peripheral Devices Market Trends

A share of around 26.5% is predicted to be held by the U.K. in 2026 in Europe, as the healthcare sector continues to improve access to minimally invasive cardiovascular treatment. The increasing burden of coronary artery disease and peripheral arterial disease, along with an aging population, is boosting demand for interventional procedures. The National Health Service (NHS) continues to extend diagnostic capacity and reduce waiting times for cardiovascular care through long-term recovery and modernization programs. Also, the National Institute for Health and Care Excellence (NICE) regularly evaluates and recommends clinically effective cardiovascular technologies. These initiatives are pushing the adoption of innovative devices that improve patient outcomes.

The global interventional cardiology and peripheral devices market is semi-consolidated, with a handful of multinational companies controlling a large share of advanced coronary and peripheral intervention technologies. The market is led by companies such as Medtronic, Boston Scientific, Abbott, Terumo, BD, Cook Medical, Teleflex, Cordis, Merit Medical Systems, and BIOTRONIK. These companies compete by delivering complete interventional portfolios that include guidewires, catheters, balloons, drug-coated balloons, coronary and peripheral stents, atherectomy systems, thrombectomy devices, embolic protection devices, and intravascular imaging platforms.

Innovation remains the leading competitive factor. Companies are investing in drug-coated technologies, intravascular lithotripsy, image-guided interventions, AI-enabled procedural planning, and devices designed for complex calcified lesions and chronic total occlusions. Clinical studies demonstrating lower restenosis rates, improved procedural success, and better long-term patient outcomes are influencing physician preference and purchasing decisions. Strategic acquisitions are also changing the competitive landscape.

Key Industry Developments:

• In December 2025, the U.S. FDA approved a manufacturing process update for Boston Scientific's WOLVERINE Coronary Cutting Balloon. The approval supported continued manufacturing and supply of the coronary plaque-modification device, which is widely used during complex percutaneous coronary interventions involving resistant and calcified coronary lesions.
• In February 2025, Teleflex announced a definitive agreement to acquire BIOTRONIK's Vascular Intervention business. The acquisition added a broad portfolio of coronary and peripheral vascular intervention devices, including drug-coated balloons, drug-eluting stents, guidewires, balloon catheters, microcatheters, and the Freesolve resorbable metallic scaffold. Teleflex stated that the transaction would significantly strengthen its global interventional cardiology and peripheral vascular business.
• In January 2025, Boston Scientific announced a definitive agreement to acquire Bolt Medical. The deal included an upfront payment of approximately US$600 million (100% enterprise value) and up to US$300 million in milestone payments. The acquisition expanded Boston Scientific's interventional cardiology portfolio with Bolt Medical's intravascular lithotripsy (IVL) platform for treating calcified coronary and peripheral artery disease.